TABLE 3.
Vitek2 AES essential and categorical agreement rates for resistant Enterobacterales subsets
| Subset (no. of isolates) | No. (%) of isolates witha: |
||||
|---|---|---|---|---|---|
| Agreement |
Error |
||||
| EA | CA | mE | ME | VME | |
| Carbapenemase | |||||
| Amoxicillin-clavulanic acid (206) | 206 (100.0) | 203 (98.5) | 3 (1.5) | 0 (0.0) | 0 (0.0) |
| Ampicillin (128) | 128 (100.0) | 128 (100.0) | 0 (0.0) | NC | 0 (0.0) |
| Ampicillin-sulbactam (128) | 128 (100.0) | 127 (99.2) | 1 (0.8) | 0 (0.0) | 0 (0.0) |
| Piperacillin-tazobactam (186) | 181 (97.3) | 172 (92.5) | 11 (5.9) | 1 (14.3) | 2 (1.2) |
| Ceftazidime-avibactam (208) | 182 (87.5) | 202 (97.1) | NA | 2 (1.4) | 4 (6.7) |
| Ceftolozane-tazobactam (179) | 165 (92.2) | 165 (92.2) | 12 (6.7) | 1 (11.1) | 1 (0.6) |
| Cefazolin (211) | 209 (99.1) | 210 (99.5) | NA | 1 (50.0) | 0 (0.0) |
| Cefoxitin (211) | 204 (96.7) | 180 (85.3) | 30 (14.2) | 0 (0.0) | 1 (0.6) |
| Cefuroxime (211) | 199 (94.3) | 206 (97.6) | 4 (1.9) | 0 (0.0) | 0 (0.0) |
| Cefepime (208) | 164 (78.8) | 173 (83.2) | 20 (9.6) | 1 (3.2) | 14 (8.3) |
| Cefotaxime (210) | 186 (88.6) | 206 (98.1) | 0 (0.0) | 1 (5.3) | 3 (1.6) |
| Cefpodoxime (185) | 181 (97.8) | 182 (98.4) | 2 (1.1) | 0 (0.0) | 1 (0.6) |
| Ceftriaxone (164) | 159 (97.0) | 161 (98.2) | 2 (1.2) | 0 (0.0) | 1 (0.7) |
| Aztreonam (211) | 199 (94.3) | 197 (93.4) | 11 (5.2) | 0 (0.0) | 3 (1.6) |
| Ertapenem (193) | 182 (94.3) | 181 (93.8) | 7 (3.6) | 2 (33.3) | 3 (1.6) |
| Imipenem (174) | 154 (88.5) | 152 (87.4) | 20 (11.5) | 2 (16.7) | 0 (0.0) |
| Meropenem (211) | 162 (76.8) | 189 (89.6) | 16 (7.6) | 5 (25.0) | 1 (0.6) |
| Meropenem-vaborbactam (197) | 179 (90.9) | 182 (92.4) | 8 (4.1) | 5 (3.5) | 2 (4.4) |
| ESBL | |||||
| Amoxicillin-clavulanic acid (122) | 119 (97.5) | 94 (77.1) | 27 (22.1) | 1 (2.2) | 0 (0.0) |
| Ampicillin (105) | 105 (100.0) | 105 (100.0) | 0 (0.0) | NC | 0 (0.0) |
| Ampicillin-sulbactam (105) | 101 (96.2) | 92 (87.6) | 10 (9.5) | 1 (5.0) | 2 (2.8) |
| Piperacillin-tazobactam (122) | 102 (83.6) | 105 (86.1) | 15 (12.3) | 2 (2.6) | 0 (0.0) |
| Ceftazidime-avibactam (122) | 110 (90.2) | 122 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Ceftolozane-tazobactam (122) | 103 (84.4) | 108 (88.5) | 6 (4.9) | 8 (9.3) | 0 (0.0) |
| Cefazolin (122) | 116 (95.1) | 116 (95.1) | NA | 1 (50.0) | 5 (4.2) |
| Cefoxitin (122) | 113 (92.6) | 101 (82.8) | 20 (16.4) | 1 (1.5) | 0 (0.0) |
| Cefuroxime (122) | 118 (96.7) | 114 (93.4) | 6 (4.9) | 0 (0.0) | 1 (0.9) |
| Cefepime (122) | 89 (73.0) | 100 (82.0) | 19 (15.6) | 1 (5.9) | 2 (2.3) |
| Cefotaxime (122) | 114 (93.4) | 117 (95.9) | 5 (4.1) | 0 (0.0) | 0 (0.0) |
| Cefpodoxime (122) | 121 (99.2) | 118 (96.7) | 4 (3.3) | 0 (0.0) | 0 (0.0) |
| Ceftriaxome (111) | 100 (90.1) | 104 (93.7) | 4 (3.6) | 3 (60.0) | 0 (0.0) |
| Aztreonam (122) | 111 (91.0) | 100 (82.0) | 13 (10.7) | 1 (10.0) | 8 (8.1) |
| Ertapenem (113) | 110 (97.3) | 108 (95.6) | 5 (4.4) | 0 (0.0) | 0 (0.0) |
| Imipenem (122) | 118 (96.7) | 118 (96.7) | 4 (3.3) | 0 (0.0) | 0 (0.0) |
| Meropenem (122) | 115 (94.3) | 116 (95.1) | 3 (2.5) | 1 (1.0) | 2 (11.1) |
| Meropenem-vaborbactam (120) | 114 (95.0) | 116 (96.7) | 2 (1.7) | 2 (1.7) | 0 (0.0) |
| tAmpCb | |||||
| Amoxicillin-clavulanic acid (32) | 30 (93.8) | 29 (90.6) | 1 (3.1) | 1 (100.0) | 1 (3.3) |
| Ampicillin (26) | 26 (100.0) | 26 (100.0) | 0 (0.0) | NC | 0 (0.0) |
| Ampicillin-sulbactam (26) | 26 (100.0) | 23 (88.5) | 3 (11.5) | NC | 0 (0.0) |
| Piperacillin-tazobactam (31) | 26 (83.9) | 24 (77.4) | 6 (19.4) | 1 (4.8) | 0 (0.0) |
| Ceftazidime-avibactam (32) | 31 (96.9) | 32 (100.0) | 0 (0.0) | 0 (0.0) | NC |
| Ceftolozane-tazobactam (31) | 25 (80.6) | 23 (74.2) | 8 (25.8) | 0 (0.0) | 0 (0.0) |
| Cefazolin (32) | 32 (100.0) | 32 (100.0) | 0 (0.0) | NC | 0 (0.0) |
| Cefoxitin (32) | 30 (93.8) | 29 (90.6) | 2 (6.3) | 0 (0.0) | 1 (3.3) |
| Cefuroxime (32) | 32 (100.0) | 29 (90.6) | 3 (9.4) | 0 (0.0) | 0 (0.0) |
| Cefepime (32) | 29 (90.6) | 29 (90.6) | 3 (9.4) | 0 (0.0) | 0 (0.0) |
| Cefotaxime (32) | 27 (84.4) | 31 (96.9) | 1 (3.1) | 0 (0.0) | 0 (0.0) |
| Cefpodoxime (31) | 31 (100.0) | 30 (96.8) | 1 (3.2) | 0 (0.0) | 0 (0.0) |
| Ceftriaxone (30) | 26 (86.7) | 28 (93.3) | 1 (3.3) | 1 (16.7) | 0 (0.0) |
| Aztreonam (32) | 23 (71.9) | 20 (62.5) | 6 (18.8) | 0 (0.0) | 6 (40.0) |
| Ertapenem (29) | 28 (96.6) | 28 (96.6) | 1 (3.5) | 0 (0.0) | 0 (0.0) |
| Imipenem (31) | 27 (87.1) | 28 (90.3) | 3 (9.7) | 0 (0.0) | 0 (0.0) |
| Meropenem (32) | 31 (96.9) | 31 (96.9) | 1 (3.1) | 0 (0.0) | 0 (0.0) |
| Meropenem-vaborbactam (32) | 31 (96.9) | 31 (96.9) | 0 (0.0) | 1 (3.1) | NC |
| Wild type | |||||
| Amoxicillin-clavulanic acid (141) | 131 (92.9) | 128 (90.8) | 9 (6.4) | 0 (0.0) | 4 (9.8) |
| Ampicillin (102) | 100 (98.0) | 95 (93.1) | 7 (6.9) | 0 (0.0) | 0 (0.0) |
| Ampicillin-sulbactam (102) | 99 (97.1) | 87 (85.3) | 13 (12.8) | 1 (1.8) | 1 (3.7) |
| Piperacillin-tazobactam (137) | 132 (96.4) | 130 (94.9) | 6 (4.4) | 1 (0.8) | 0 (0.0) |
| Ceftazidime-avibactam (145) | 138 (95.2) | 145 (100.0) | 0 (0.0) | 0 (0.0) | NC |
| Ceftolozane-tazobactam (130) | 124 (95.4) | 124 (95.4) | 3 (2.3) | 3 (2.5) | 0 (0.0) |
| Cefazolin (148) | 144 (97.3) | 132 (89.2) | 0 (0.0) | 1 (1.1) | 1 (1.7) |
| Cefoxitin (148) | 141 (95.3) | 136 (91.9) | 9 (6.1) | 1 (1.0) | 2 (5.9) |
| Cefuroxime (148) | 142 (95.9) | 130 (87.8) | 7 (4.7) | 0 (0.0) | 0 (0.0) |
| Cefepime (145) | 139 (95.9) | 141 (97.2) | 4 (2.8) | 0 (0.0) | 0 (0.0) |
| Cefotaxime (148) | 142 (95.9) | 146 (98.7) | 1 (0.7) | 0 (0.0) | 1 (4.0) |
| Cefpodoxime (134) | 130 (97.0) | 128 (95.5) | 5 (3.7) | 0 (0.0) | 1 (4.2) |
| Ceftriaxone (130) | 129 (99.2) | 130 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Aztreonam (148) | 146 (98.6) | 145 (98.0) | 2 (1.4) | 0 (0.0) | 1 (4.8) |
| Ertapenem (141) | 140 (99.3) | 140 (99.3) | 1 (0.7) | 0 (0.0) | 0 (0.0) |
| Imipenem (110) | 101 (91.8) | 109 (99.1) | 1 (0.9) | 0 (0.0) | 0 (0.0) |
| Meropenem (148) | 145 (98.0) | 147 (99.3) | 1 (0.7) | 0 (0.0) | 0 (0.0) |
| Meropenem-vaborbactam (148) | 147 (99.3) | 147 (99.3) | 0 (0.0) | 1 (0.7) | NC |
a
EA, essential agreement; CA, categorical agreement; mE, minor error; ME, major error; VME, very major error; NA, not applicable (no intermediary breakpoint); NC, not calculable (denominator null).
b
tAmpC, transferrable AmpC.